BC Week In Review | Jul 18, 2016
Clinical News

OneCrinone regulatory update

Juniper said Japan approved OneCrinone progesterone as a luteal phase supplementation in assisted reproductive treatment. Merck has rights to the 8% progesterone bioadhesive vaginal gel outside of the U.S. from Juniper. The pharma markets the...
BC Week In Review | Sep 1, 2014
Company News

Columbia Laboratories, XenoGesis deal

Columbia Laboratories’ CRO subsidiary, Molecular Profiles Ltd. , partnered with XenoGesis to provide preclinical and formulation development services. XenoGesis will provide expertise in preclinical drug metabolism and pharmacokinetics ( DMPK ) to support Molecular Profiles’ pharmaceutical development services....
BC Week In Review | Sep 23, 2013
Company News

Columbia Laboratories, Molecular Profiles deal

Columbia Labs acquired CRO Molecular Profiles for $25 million comprising $16.7 million in cash and 1.1 million Columbia shares. Molecular Profiles CEO and co-founder Nikin Patel joins Columbia's board. Molecular Profiles performs contract R&D, clinical...
BC Week In Review | Apr 15, 2013
Company News

Columbia Laboratories, Merck KGaA sales and marketing update

Columbia Labs said it has extended by five years through May 2020 an amended 1995 deal granting Merck's Merck Serono S.A. unit exclusive marketing rights to Crinone progesterone outside the U.S. Crinone, a progesterone gel...
BC Week In Review | Oct 29, 2012
Clinical News

Crinone regulatory update

Watson said FDA denied the company's request for a formal dispute resolution related to a February complete response letter for Prochieve vaginal progesterone gel. The company was seeking approval for Prochieve to prevent preterm birth...
BC Extra | Oct 27, 2012
Company News

FDA denies Watson's formal dispute resolution request

Watson Pharmaceuticals Inc. (NYSE:WPI) said FDA denied the company's request for a formal dispute resolution related to a February complete response letter for Prochieve vaginal progesterone gel. The company was seeking approval for Prochieve to...
BioCentury | Apr 2, 2012
Finance

Doubling down

Biotech investors lifted valuations across the board last quarter and made a handful of big bets that were driven by potential acquisitions, lawsuit settlements, strong earnings and positive clinical and regulatory news. At least one...
BC Week In Review | Mar 19, 2012
Company News

Columbia Laboratories genitourinary news

Columbia hired Cowen and Co. LLC as a financial advisor to evaluate strategic transactions. In its 4Q11 earnings release on March 8, the company said it will evaluate "potential strategic transactions that will add value...
BC Week In Review | Mar 5, 2012
Clinical News

Prochieve regulatory update

Watson said it received a complete response letter from FDA for an NDA for Prochieve vaginal progesterone gel to reduce the risk of preterm birth in women with short uterine cervical length in the mid-trimester...
BC Week In Review | Mar 5, 2012
Company News

Columbia Laboratories genitourinary news

Columbia reduced headcount by 10 (42%) to 14 to save cash. Columbia said the reduction, which comprises mostly R&D and administrative positions, is expected to save over $1.5 million annually. The company said it is...
Items per page:
1 - 10 of 66